Literature DB >> 22736064

Clear and present danger? Engineered nanoparticles and the immune system.

Bengt Fadeel1.   

Abstract

The innate immune system is the first line of defense against microbial invasion and involves the recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors on the surface of phagocytic cells. The immune system also responds to tissue damage, a process that is triggered by so-called danger- or damage-associated molecular patterns (DAMPs) or "alarmins". How do physico-chemical properties e.g., size, shape, surface charge and solubility affect immune interactions of nanoparticles? Does the adsorption of biomolecules onto the surface of nanoparticles dictate subsequent immune responses? Do engineered nanoparticles per se act as "alarmins" or does the bio-corona on nanoparticles convey a new "identity" and allow innocuous nanoparticles to present NAMPs (nanoparticle-associated molecular patterns)? Finally, what are the parameters that determine particle clearance or biodegradation in a living system? Understanding nano-immuno-interactions is critical for the safe application of engineered nanoparticles in medicine.

Mesh:

Substances:

Year:  2012        PMID: 22736064     DOI: 10.4414/smw.2012.13609

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  30 in total

Review 1.  Toxicological effect of engineered nanomaterials on the liver.

Authors:  A Kermanizadeh; B K Gaiser; H Johnston; D M Brown; V Stone
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

2.  Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.

Authors:  Ryan F Russell; Jacqueline U McDonald; Laura Lambert; John S Tregoning
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  Developing Xenopus embryos recover by compacting and expelling single wall carbon nanotubes.

Authors:  Brian D Holt; Joseph H Shawky; Kris Noel Dahl; Lance A Davidson; Mohammad F Islam
Journal:  J Appl Toxicol       Date:  2015-07-07       Impact factor: 3.446

Review 4.  Convergence of nanotechnology and cancer prevention: are we there yet?

Authors:  David G Menter; Sherri L Patterson; Craig D Logsdon; Scott Kopetz; Anil K Sood; Ernest T Hawk
Journal:  Cancer Prev Res (Phila)       Date:  2014-07-24

5.  The Effect of Size and Shape of RNA Nanoparticles on Biodistribution.

Authors:  Daniel L Jasinski; Hui Li; Peixuan Guo
Journal:  Mol Ther       Date:  2017-12-22       Impact factor: 11.454

6.  Immune responses to engineered nanomaterials: current understanding and challenges.

Authors:  Nasser B Alsaleh; Jared M Brown
Journal:  Curr Opin Toxicol       Date:  2017-11-24

Review 7.  Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.

Authors:  Marina A Dobrovolskaia; Scott E McNeil
Journal:  J Control Release       Date:  2013-06-03       Impact factor: 9.776

8.  Surface Coating of Nanoparticles Reduces Background Inflammatory Activity while Increasing Particle Uptake and Delivery.

Authors:  Brittany A Moser; Rachel C Steinhardt; Aaron P Esser-Kahn
Journal:  ACS Biomater Sci Eng       Date:  2016-12-01

Review 9.  The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery.

Authors:  Claudia Corbo; Roberto Molinaro; Alessandro Parodi; Naama E Toledano Furman; Francesco Salvatore; Ennio Tasciotti
Journal:  Nanomedicine (Lond)       Date:  2015-12-11       Impact factor: 5.307

Review 10.  Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.

Authors:  Marina A Dobrovolskaia
Journal:  J Control Release       Date:  2015-09-05       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.